Belite Bio's Tinlarebant Shows Promise in Stargardt Disease Trial

Ticker: BLTE · Form: 6-K · Filed: Dec 1, 2025 · CIK: 1889109

Belite Bio, INC 6-K Filing Summary
FieldDetail
CompanyBelite Bio, INC (BLTE)
Form Type6-K
Filed DateDec 1, 2025
Risk Levelmedium
Pages1
Reading Time1 min
Sentimentbullish

Sentiment: bullish

Topics: clinical-trial-results, pharmaceutical, stargardt-disease

TL;DR

Belite Bio's Stargardt drug tinlarebant shows positive Phase 3 results, potentially a breakthrough for an untreatable disease.

AI Summary

On December 1, 2025, Belite Bio, Inc. announced positive topline results from its pivotal global Phase 3 DRAGON trial for tinlarebant in adolescents with Stargardt disease. This trial is significant as Stargardt disease was previously considered untreatable. The company filed a Form 6-K to report these findings.

Why It Matters

This announcement offers potential new hope for patients with Stargardt disease, a condition with limited treatment options, by demonstrating positive results in a Phase 3 trial.

Risk Assessment

Risk Level: medium — While the results are positive, the drug still needs regulatory approval and market adoption, and the long-term efficacy and safety are yet to be fully established.

Key Players & Entities

FAQ

What specific disease does tinlarebant target, and what was the outcome of the Phase 3 DRAGON trial?

Tinlarebant targets Stargardt disease in adolescents, and the Phase 3 DRAGON trial announced positive topline results.

When did Belite Bio, Inc. announce these trial results?

Belite Bio, Inc. announced the results on December 1, 2025.

What type of SEC filing was used to report these results?

A Form 6-K report was filed by Belite Bio, Inc. to report these results.

What is the significance of Stargardt disease in the context of this announcement?

Stargardt disease was previously considered untreatable, making the positive results for tinlarebant a significant development.

Where is Belite Bio, Inc. headquartered?

Belite Bio, Inc. is headquartered at 12750 High Bluff Drive, Suite 475, San Diego, CA 92130.

Filing Stats: 308 words · 1 min read · ~1 pages · Grade level 12.5 · Accepted 2025-12-01 06:01:35

Filing Documents

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15b-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2025 Commission File Number: 001-41359 Belite Bio, Inc (Exact name of registrant as specified in its charter) Not Applicable (Translation of Registrant ’s name into English) 12750 High Bluff Drive Suite 475, San Diego, CA 92130 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F On December 1, 2025, Belite Bio, Inc (the “Company”) issued a press release entitled “New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease.” A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. On December 1 2025, the Company updated its investor presentation. A copy of this presentation is attached hereto as Exhibit 99.2 and is incorporated herein by reference. This Report on Form 6-K and the related exhibits are incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933 and shall be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Exhibit No. Description of Exhibit 99.1 Press Release 99.2 Investor Presentation SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Belite Bio, Inc By: /s/ Yu-Hsin Lin Name: Yu-Hsin Lin Title: Chief Executive Officer and Chairman Date: December 1, 2025

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing